MultiCASE publishes no price for CASE Ultra. Its FAQ says the price depends on the length of the license, the number of endpoints and the number of users, and asks you to request a quote. Search for the number and you get the FAQ, the product page and a solicitation notice. What a company pays for a year of CASE Ultra is not written anywhere public.
US federal agencies buy it too, and their awards are public. Seven are written to MultiCASE, Inc. from 2007 to 2027, about $341,000 in total. Five of them are one FDA license renewed every July, which makes them unusually easy to read.
How much does CASE Ultra cost?
The FDA has paid $15,000 a year for CASE Ultra and META Ultra since July 2020, including license, maintenance and support. It renewed at that figure in 2021 and 2022, then signed a term to July 2027 at $60,000, which is the same $15,000 a year. Before 2020 it paid $45,300 for two years, about $22,650 a year. These are government figures, so read them as a floor for a commercial quote rather than a forecast.
FDA, MultiCASE license per year, every term ending in July
Grey bars are one two year award divided by two. Violet bars from 2023 are one four year award divided by four.
Why the price fell a third in 2020
The step from about $22,650 a year to $15,000 is a 34 percent drop on the same July anniversary. The record does not list line items, so it cannot say why. MultiCASE prices by endpoints, though, and a license that covered fewer endpoints from 2020 would produce exactly this shape. The wording also changed, from "MultiCASE software" to a named pair, CASE Ultra and META Ultra, which points to a tighter scope rather than a discount.
For a buyer, that is the most useful thing on the record. If your quote covers endpoints you will never run, the FDA paid a third less once its license matched its work. List the endpoints you need, from bacterial mutagenicity for ICH M7 down to whatever else your safety plan asks for, and price only those.
The seven year flat rate
From 2020 the price did not move at all. Three one year renewals at $15,000, then a term to July 2027 at $60,000. That is seven years without an uplift, at a time when most vendors on our other pricing pages added 3 to 5 percent a year. The 2023 term followed an FDA request for quotes for CASE Ultra and META Ultra to support computational toxicology on chemicals in tobacco products, so it is the same program buying the same pair.
If your renewal arrives with an increase, the record gives you a clean counterexample. A flat multi year renewal is something MultiCASE has signed, and the federal record shows it.
What one license covers
MultiCASE's FAQ answers the seat question directly. An annual license covers a single machine, with a discount for additional machines, and it allows the program to be installed on a server and used by several users through remote desktop. Upgrades, maintenance and technical support are inside the annual fee. That is a cheaper structure for a small safety group than per user pricing, because three toxicologists can share one server install.
There is also a pay per test option for CASE Ultra and META Ultra: you buy a fixed number of queries up front instead of renewing every year. For a team that runs an impurity assessment a handful of times a year, that can cost far less than a license. MultiCASE says it offers limited free trials case by case.
What the two older awards tell you
| Term | Buyer | How the award describes it | Amount |
|---|---|---|---|
| Jun 2007 to Oct 2011 | CDC | MultiCASE software | $15,835 |
| Apr 2011 to Nov 2011 | Army | Base year, bioinformatics software license | $174,934 |
| Jul 2018 to Jul 2020 | FDA | MultiCASE software | $45,300 |
| Jul 2020 to Jul 2021 | FDA | MultiCASE software subscription | $15,000 |
| Jul 2021 to Jul 2022 | FDA | CASE Ultra and META Ultra license and maintenance support | $15,000 |
| Jul 2022 to Jul 2023 | FDA | CASE Ultra and META Ultra license and maintenance | $15,000 |
| Jun 2023 to Jul 2027 | HHS, for the FDA | CASE Ultra and META Ultra license and maintenance | $60,000 |
The CDC paid $15,835 on a term recorded from 2007 to 2011, with no detail on what it covered, so it is not annualized here. The Army's 2011 base year at $174,934 is more than eleven FDA years. It is described as a bioinformatics software license and is far larger than anything else MultiCASE has sold the government, so read it as a wide or custom scope, not as the going rate. The rate is the FDA's $15,000.
How CASE Ultra compares with Derek Nexus and Leadscope
ICH M7 asks for two complementary (Q)SAR methods to assess mutagenic impurities, one expert rule based and one statistical. MultiCASE, Lhasa and Instem are the three vendors most M7 teams shortlist, and all three have a public federal figure.
| Tool | Method | Public annual figure | Licensed by |
|---|---|---|---|
| MultiCASE CASE Ultra with META Ultra | Statistical (Q)SAR with structural alerts, plus metabolite prediction | $15,000 a year, FDA, 2020 to 2027 | One machine, server use by remote desktop |
| Lhasa Derek, Meteor and Sarah Nexus | Expert rules plus statistical mutagenicity, plus metabolism | $14,651 a year, EPA, five users, 2025 | Users at a site, with membership |
| Instem Leadscope | Expert alerts and statistical models, toxicity database | $27,450 a year, NIH product suite, 2013 to 2022 | Concurrent users, hosted or installed |
CASE Ultra with META Ultra and Lhasa's three product bundle land within a few hundred dollars of each other on government terms. Leadscope's product suite runs nearly twice that, though it includes a large toxicity database. The full Leadscope record is on the Leadscope pricing page, and the Lhasa side, including the Derek and Sarah pair that many M7 submissions use, is in Derek Nexus pricing. Where CASE Ultra wins is the licensing unit: one server install shared by remote desktop is hard to beat for a small team.
Can CASE Ultra be used for ICH M7?
Yes. MultiCASE offers an ICH M7 application for bacterial mutagenicity, and CASE Ultra's models are validated under OECD guidelines and come with QMRF reports, which is the documentation a reviewer expects. Before you sign, confirm whether the quote covers one M7 methodology or both, since the guideline asks for an expert rule based and a statistical prediction side by side.
Teams that store every prediction in a warehouse for submission can trace each call back to the model run that made it with data lineage software, which matters when a reviewer asks which model version produced a negative.
What a mutagenicity alert does not tell an antibacterial team
CASE Ultra predicts toxicity. It does not predict whether a compound inhibits Staphylococcus aureus or Klebsiella pneumoniae, and for an anti-infective series that is the other half of the decision. Nitrofurantoin and metronidazole both carry a nitroaromatic alert and both are approved antibacterials, because their potency justified the testing. A compound with an alert and real activity deserves an Ames test. A compound with an alert and no activity deserves nothing.
That is why it pays to read potency first. A predicted MIC band per organism across the ESKAPE panel, with the mechanism class and the closest published analogs, tells you which compounds are worth an impurity assessment at all. MIC prediction software does that in seconds per compound, and Lab is $149 a month, $1,788 a year. One FDA year of CASE Ultra would pay for about 8.4 years of it. The two are not substitutes. One decides what is active, the other decides what is safe, and the cheaper question should go first. If you are still deciding between building a toxicity or activity model yourself and buying one, the QSAR software comparison lays out what each package needs from you.